We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Odonate Therapeutics Inc | NASDAQ:ODT | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.12 | 1.11 | 1.16 | 0 | 01:00:00 |
Odonate Therapeutics, Inc. (NASDAQ: ODT) today announced that on January 6, 2022 it received written notice from The Nasdaq Stock Market LLC (“Nasdaq”) notifying Odonate that Nasdaq believes that Odonate is a "public shell" pursuant to Listing Rule 5101, and that the continued listing of its securities is no longer warranted. Odonate will not appeal this determination. Therefore, Odonate expects the trading of its common stock on The Nasdaq Stock Market to be suspended at the opening of business on January 18, 2022, and that Nasdaq will file a Form 25-NSE with the U.S. Securities and Exchange Commission (the “SEC”), which will remove Odonate’s securities from listing and registration on The Nasdaq Stock Market. Additionally, Odonate intends to file with the SEC a Form 15 requesting the suspension of the Company’s reporting obligations.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220107005100/en/
Odonate Therapeutics, Inc. Michael Hearne Chief Financial Officer (332) 208-7611 mhearne@odonate.com
1 Year Odonate Therapeutics Chart |
1 Month Odonate Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions